Grant: Strategic Projects - Group
McGill University
$212,822.00
Tissue segmentation in MRI
FY 2007-08
Summary
Multiple sclerosis (MS) is the most common neurological disease of young adults, affecting approximately 50,000 people in Canada. The disease is characterized by transient attacks on the central nervous system and results in numbness or weakness of a limb, in coordination, vertigo or visual dysfunction. At present there is no cure. Over the last decade, a number of new therapies have been approved for clinical use based primarily on demonstration of their ability to reduce the number of new lesions. These drugs reduce the number of attacks by 30-50%. Evaluation of newer, more efficient treatments requires clinical trails where the "burden of disease" is measured by identification of new lesions seen in magnetic resonance imaging (MRI). The state of the art for lesion identification in the pharmaceutical industry consists of subjective manual or semi-manual procedures. This process is subject to inter- and intra-observer variability that diminishes the statistical power to detect a drug effect. To address this problem, one must increase the number of subjects in the study a very expensive option.The goal of this project is to develop a robust, accurate and fully automatic tissue classification technique that can identify healthy and diseased tissues when applied to real clinical MRI data. Efficient successful drug development would benefit from such a technique because the improved statistical power to detect change can be used to diminish the number of subjects required or reduce the amount of time required to detect a treatment effect in a clinical trials (or both). In either case, trial costs are reduced, thus enabling the evaluation more candidate treatments. This procedure would also benefit academic research laboratories for the analysis of MRI data to further understand the disease process in MS in order to find finding better, more efficient treatments.
Program
Strategic Projects - Group
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
350547-2007
Name nom
Collins, Louis
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2007
Award amount
212822
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1042
Committee name en
Strategic Projects Selection Panel - Biomedical Technologies
Committee name fr
Comité de sélection des projets stratégiques - Technologies biomédicales
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
3
Application title
Tissue segmentation in MRI
Keyword
NA
Application summary
Multiple sclerosis (MS) is the most common neurological disease of young adults, affecting approximately 50,000 people in Canada. The disease is characterized by transient attacks on the central nervous system and results in numbness or weakness of a limb, in coordination, vertigo or visual dysfunction. At present there is no cure. Over the last decade, a number of new therapies have been approved for clinical use based primarily on demonstration of their ability to reduce the number of new lesions. These drugs reduce the number of attacks by 30-50%. Evaluation of newer, more efficient treatments requires clinical trails where the "burden of disease" is measured by identification of new lesions seen in magnetic resonance imaging (MRI). The state of the art for lesion identification in the pharmaceutical industry consists of subjective manual or semi-manual procedures. This process is subject to inter- and intra-observer variability that diminishes the statistical power to detect a drug effect. To address this problem, one must increase the number of subjects in the study a very expensive option.The goal of this project is to develop a robust, accurate and fully automatic tissue classification technique that can identify healthy and diseased tissues when applied to real clinical MRI data. Efficient successful drug development would benefit from such a technique because the improved statistical power to detect change can be used to diminish the number of subjects required or reduce the amount of time required to detect a treatment effect in a clinical trials (or both). In either case, trial costs are reduced, thus enabling the evaluation more candidate treatments. This procedure would also benefit academic research laboratories for the analysis of MRI data to further understand the disease process in MS in order to find finding better, more efficient treatments.